To include your compound in the COVID-19 Resource Center, submit it here.

Medarex pipeline

Medarex pipeline

Therapeutics
Product [Partner] Target Status [Lead indication]
Ipilimumab (MDX-010) [Bristol-Myers Squibb Co. (NYSE:BMY)] CTLA-4 (CD152) receptor Ph III [melanoma]
MDX-1100 Chemokine CXC motif ligand 10 (CXCL10) (IP-10) Ph

Read the full 396 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE